Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 31.08M | 1.20M | 139.00K | 298.00K | 24.00M |
Gross Profit | 30.46M | 1.12M | -288.00K | -54.75M | 22.07M |
EBITDA | -184.29M | -163.46M | -98.74M | -86.66M | -41.10M |
Net Income | -200.40M | -177.12M | -103.13M | -88.27M | -70.18M |
Balance Sheet | |||||
Total Assets | 298.42M | 229.43M | 194.30M | 136.91M | 203.79M |
Cash, Cash Equivalents and Short-Term Investments | 237.96M | 170.03M | 138.36M | 86.74M | 152.28M |
Total Debt | 108.40M | 106.06M | 55.29M | 2.28M | 12.81M |
Total Liabilities | 152.47M | 136.32M | 77.17M | 23.31M | 47.42M |
Stockholders Equity | 145.95M | 93.11M | 117.12M | -1.49B | 156.37M |
Cash Flow | |||||
Free Cash Flow | -179.81M | -162.37M | -90.18M | -88.24M | -143.06M |
Operating Cash Flow | -178.78M | -161.90M | -88.85M | -87.02M | -142.97M |
Investing Cash Flow | -15.38M | -49.94M | -71.08M | 2.11M | 380.76M |
Financing Cash Flow | 238.35M | 187.96M | 142.21M | 22.71M | -147.64M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | $115.43M | 34.52 | 10.42% | ― | 0.18% | -55.15% | |
58 Neutral | $446.71M | ― | -86.09% | ― | 1250.63% | 37.24% | |
57 Neutral | $341.69M | ― | 322.49% | ― | -30.66% | 36.48% | |
54 Neutral | $271.24M | ― | -198.47% | ― | ― | -38.86% | |
52 Neutral | $7.35B | -0.07 | -63.71% | 2.81% | 16.17% | 0.03% | |
45 Neutral | $492.59M | ― | -32.12% | ― | ― | 10.98% | |
35 Underperform | $386.41M | ― | -500.57% | ― | ― | 81.94% |
On July 3, 2025, Lexicon Pharmaceuticals received a letter from Nasdaq indicating eligibility for an additional 180-day period to regain compliance with the minimum $1 bid price requirement for its common stock. The company applied to transfer its stock from the Nasdaq Global Select Market to the Nasdaq Capital Market, which was approved, and the transfer will occur on July 7, 2025. This move allows Lexicon Pharmaceuticals more time to meet the bid price requirement, with plans to potentially implement a reverse stock split if necessary.
The most recent analyst rating on (LXRX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Lexicon Pharmaceuticals stock, see the LXRX Stock Forecast page.
On June 2, 2025, Lexicon Pharmaceuticals held its annual meeting of stockholders to vote on several key proposals. The meeting resulted in the election of Class I Directors, amendments to the company’s equity incentive plans, approval of a potential reverse stock split, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2025. These decisions reflect strategic moves to enhance corporate governance and financial management, potentially impacting shareholder value and market perception.
The most recent analyst rating on (LXRX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Lexicon Pharmaceuticals stock, see the LXRX Stock Forecast page.